To treat NSCLC, monotherapy with gefitinib, erlotinib, afatinib, or dacomitinib, is successfully used in advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutations. Here, EGFR is linked to non-small cell lung carcinoma.